Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blood Disorders Overtake Cancer On EMA’s PRIME Scheme

Executive Summary

uniQure has become the third company to get accepted on the European Medicines Agency’s PRIME (priority medicines) scheme for a gene therapy for hemophilia, making hematology-hemostaseology the most common therapeutic areas for products on the scheme.

You may also be interested in...



Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Getting On – And Staying In – the EMA’s PRIME Scheme

Companies won’t necessarily lose their place on the European Medicines Agency’s priority medicines scheme if a competing product gets to market first. And they shouldn’t be put off by the fact that competing products are already on the scheme.

Hemophilia B Gene Therapy Market PRIMEd In Europe

UniQure’s gene therapy, AMT-060, has been accepted into the European Medicines Agency’s priority medicines scheme, PRIME, a move likely to intensify the race to market of a small group of gene therapies for hemophilia B, all currently in Phase I/II studies.

Topics

UsernamePublicRestriction

Register

PS120514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel